Basic & Clinical Medicine ›› 2021, Vol. 41 ›› Issue (7): 1056-1059.

• Mini Reviews • Previous Articles     Next Articles

Research progress of mesenchymal stem cells in the treatment of pulmonary fibrosis

CHEN Min-jia, WANG Xiao-yue, CHEN Ke-hong, LU Hong-xiang*   

  1. Department of Gastroenterology, Daping Hospital, the Army Medical University, Chongqing 400042, China
  • Received:2020-08-04 Revised:2020-12-15 Online:2021-07-05 Published:2021-06-17
  • Contact: *

Abstract: There is no effective therapeutic drug and intervention method for pulmonary fibrosis(PF). There are many mechanisms of using mesenchymal stem cell in the treatment of idiopathic pulmonary fibrosis(IPF), radiation pulmonary fibrosis(RPF) and other types of PF as follows: paracrine impact, release of leukocyte mediator-1 receptor antagonist, inhibition of the expression of interleukin-1 and tumor necrosis factor-α, and resistant to tissue inflammation,increase of signal transduction for hepatocyte growth factor(HGF),inhibition of PI3K/AKT/mTOR activation and epithelial mesenchymal transformation(EMT) in alveolar Ⅱ epithelial cells(ATⅡ),lung tissue apoptosis and fibrosis, promotion of tissue anti-inflammatory and anti-fibrosis, and to delay organ fibrosis. This review may function as a potential orientation for the treatment of organ fibrosis with MSCs.

Key words: mesenchymal stem cells(MSCs), therapy, pulmonary fibrosis(PF), Wnt signaling pathway, hepatocyte growth factor(HGF)

CLC Number: